Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

52.88 -1.21 (-2.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioMarin Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
This Zimmer Biomet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
 
Via Benzinga
News headline image
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗
BioMarin presents a strong value investment case with low valuation multiples, robust profitability, and a healthy balance sheet, all while showing solid growth potential. 
Via Chartmill
News headline image
The 5 Most Interesting Analyst Questions From BioMarin Pharmaceutical’s Q3 Earnings Call
BioMarin Pharmaceutical’s third quarter results reflected steady top-line growth, with management highlighting enzyme therapies and the Skeletal Conditions business as main contributors. CEO Alexander... 
Via StockStory
Topics Earnings
News headline image
Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday ↗
Although the company recorded higher sales overall, it's decided to divest one of its products. 
Via The Motley Fool
News headline image
Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 4.5% in the morning session after the company reported third-quarter earnings, which featured a significant earnings miss but a... 
Via StockStory
Topics Earnings Economy Government
News headline image
Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings ↗
 
Via Benzinga
News headline image
BMRN Q3 Deep Dive: Product Expansion and Portfolio Shifts Define Outlook
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.1% year on year to $776.1 million. The company’s outlook for the full year was... 
Via StockStory
News headline image
BioMarin (BMRN) Q3 2025 Earnings Call Transcript ↗
BioMarin (BMRN) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Reports Mixed Q3 2025 Results with Revenue Growth but Earnings Miss ↗
BioMarin's Q3 2025 results show mixed performance with revenue growth but a significant earnings miss, while the company raises its full-year outlook. 
Via Chartmill
Topics Earnings
News headline image
BioMarin Pharmaceutical (NASDAQ:BMRN) Posts Q3 Sales In Line With Estimates
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.1% year on year to $776.1 million. The company’s outlook for the full year was... 
Via StockStory
News headline image
BioMarin Pharmaceutical (BMRN) Reports Q3: Everything You Need To Know Ahead Of Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results this Monday after market close. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
What to Expect from Biomarin Pharmaceutical's Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For October 27, 2025 ↗
 
Via Benzinga
News headline image
3 of Wall Street’s Favorite Stocks to Target This Week
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
News headline image
1 Healthcare Stock Worth Investigating and 2 We Question
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
News headline image
1 Mid-Cap Stock to Research Further and 2 That Underwhelm
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
News headline image
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
News headline image
Is BioMarin Pharmaceutical Inc Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
6 Analysts Assess BioMarin Pharmaceutical: What You Need To Know ↗
 
Via Benzinga
News headline image
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗
BioMarin is a strong value stock with a low P/E ratio, robust financial health, and solid profitability, offering a compelling safety margin for investors. 
Via Chartmill
News headline image
Peering Into BioMarin Pharmaceutical's Recent Short Interest ↗
 
Via Benzinga
News headline image
2 Profitable Stocks on Our Watchlist and 1 We Turn Down
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
News headline image
Reflecting On Therapeutics Stocks’ Q2 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how BioMarin Pharmaceutical... 
Via StockStory
Topics Artificial Intelligence
News headline image
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment ↗
BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study. 
Via Benzinga
News headline image
Why BioMarin Pharmaceutical (BMRN) Stock Is Down Today
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) fell 2.8% in the morning session after HC Wainwright & Co. initiated coverage on the stock with a Neutral rating and a $60 price target. 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
Forecasting The Future: 5 Analyst Projections For BioMarin Pharmaceutical ↗
 
Via Benzinga
News headline image
This Duolingo Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
2 Growth Stocks to Stash and 1 We Ignore
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s... 
Via StockStory
News headline image
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): A Value Investing Case Study in Undervaluation ↗
BioMarin Pharmaceutical (BMRN) is a top value investing pick, trading at a discount with strong financial health, high profitability, and solid growth potential. 
Via Chartmill
News headline image
2 Safe-and-Steady Stocks to Keep an Eye On and 1 Facing Challenges
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.